FIELD: chemistry.
SUBSTANCE: present invention relates to compounds of formula I, where Z is selected from the group consisting of (C3-C8)heterocycloalkyl, heteroaryl, phenyl, where any of said heteroaryl, heterocycloalkyl and phenyl can be optionally substituted with one or more groups selected from (C1-C3)alkyl-, halogen, (C1-C6)haloalkyl-; R1 is H or (C1-C4)alkyl; R2 is selected from the group consisting of heteroaryl (C1-C4)alkyl-, (C3-C8)heterocycloalkyl-(C1-C6)alkyl-, heteroaryl-(C1-C6)hydroxyalkyl, (RARB)N(O)C(C1-C4) alkylene-, where any of said alkyl, alkylene, heteroaryl and heterocycloalkyl can be optionally substituted with one or more groups selected from (C1-C3)alkyl, (C1-C6)haloalkyl, halogen, oxo group, heteroaryl; RA and RB in each case are independently H or selected from the group consisting of (C1-C4)alkyl-, (C1-C6)haloalkyl, or RA and RB together with the nitrogen atom to which they are attached, can form 5- or 6-member saturated heterocyclic monocyclic ring system, optionally containing an additional heteroatom, which is a nitrogen or oxygen atom, which can be optionally substituted with one or more groups selected from (C1-C4)alkyl and an oxo group; Y is selected from a group consisting of -ORD, RCSO2, heteroaryl, (C3-C8)heterocycloalkyl, where any of said heteroaryl and heterocycloalkyl can be optionally substituted with one or more groups selected from (C1-C3)alkyl; RC in each case is H or is selected from the group consisting of (C1-C6)alkyl, (RARB)N-; RD in each case is selected from a group consisting of H, (C1-C6)alkyl, (C3-C8)heterocycloalkyl-(C1-C6) alkyl-, RCOC(O)(C1-C4) alkylene-, (C3-C8)heterocycloalkyl, RCO(C1-C4) alkylene-, (RARB)N(O)C(C1-C4) alkylene, where any said heterocycloalkyl can be optionally substituted with one or more groups selected from (C1-C3)alkyl-; J is H. Also disclosed is a pharmaceutical composition, a compound of formula Ib and use thereof as an intermediate compound when producing compounds of formula (I).
EFFECT: compounds of the present invention are capable of inhibiting P2X purinoreceptor 3 and can be used in the treatment of a variety of disorders, the mechanism of development of which is associated with P2X3 receptors, such as respiratory diseases, including cough, asthma, idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD).
18 cl, 10 tbl, 190 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PYRIMIDINE-2,4-DIAMINE DERIVATIVES FOR CANCER TREATMENT | 2013 |
|
RU2672916C2 |
| INHIBITOR COMPOUNDS | 2013 |
|
RU2673079C2 |
| DERIVATIVES OF 3-(5-CHLORO-2-OXOBENZO[D]OXAZOL-3(2H)-YL)PROPANOIC ACID AS KMO INHIBITORS | 2014 |
|
RU2693016C1 |
| OXADIAZOLE-BASED CHANNEL INHIBITORS WITH TRANSIENT POTENTIAL | 2019 |
|
RU2818244C2 |
| OXADIAZOLAMINE DERIVATIVES AS HISTONE DEACETYLASE 6 INHIBITOR AND PHARMACEUTICAL COMPOSITION CONTAINING THEM | 2016 |
|
RU2695133C1 |
| SUBSTITUTED CARBONUCLEOSIDES DERIVATIVES USED AS ANTICANCER AGENTS | 2017 |
|
RU2712944C1 |
| DERIVATIVES OF 3-(6-CHLORO-3-OXO-3.4-DIHYDRO-(2H)-1.4-BENZOXASIN-4-YL)PROPIONIC ACID AND THEIR USE AS KMO INHIBITORS | 2016 |
|
RU2746001C2 |
| PYRROLOPYRIMIDINES AS CFTR POTENTIATORS | 2017 |
|
RU2757457C2 |
| INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR | 2013 |
|
RU2679130C2 |
| QUINOLINE CARBOXAMIDE AND QUINOLINE CARBONITRILE DERIVATIVES AS mGluR2 NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS AND USE THEREOF | 2012 |
|
RU2610262C2 |
